Physician profile
Louis J Arno
NPI 1720185978
$9,973.47
in general payments reported to CMS, 2019-2025
31 companies · $1,921 in 2025
The $1,921 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $1,232 · 2021: $1,434 · 2022: $1,226 · 2023: $919 · 2024: $1,505 · 2025: $1,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,305 · Education: $40.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,305.00 |
| Education | $40.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,892.97 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,257.96 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $640.91 | 2019-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $633.35 | 2019-2024 | Yupelri |
| Genzyme Corporation | $407.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $371.68 | 2019-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $320.83 | 2019-2020 | |
| Grifols USA, LLC | $315.04 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $258.06 | 2019-2024 | Xolair |
| Amgen INC. | $243.30 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $209.91 | 2019-2024 | |
| Electromed, INC. | $192.15 | 2019-2025 | Smartvest |
| Philips North America LLC | $174.11 | 2019-2025 | Vest Therapy Und |
| Verona Pharma, INC. | $125.62 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $120.43 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $118.84 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Mallinckrodt Hospital Products INC. | $91.48 | 2021-2025 | Acthar |
| Insmed, INC. | $91.26 | 2022-2025 | Arikayce |
| Inspire Medical Systems, INC. | $76.90 | 2023-2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $76.57 | 2020-2022 | |
| Baxter Healthcare | $68.85 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $46.21 | 2023-2024 | Tyvaso, Orenitram |
| Shire North American Group INC | $38.65 | 2019 | |
| Ani Pharmaceuticals, INC. | $34.88 | 2024-2025 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $34.42 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $28.09 | 2022-2024 | Aralast |
| Circassia INC. | $27.01 | 2019 | |
| Jazz Pharmaceuticals INC. | $25.27 | 2021-2022 | |
| Harmony Biosciences LLC | $20.35 | 2023 | Wakix |
| Paratek Pharmaceuticals, INC. | $18.59 | 2021 | |
| Mallinckrodt Enterprises LLC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Arno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.